Bionano Genomics, Inc. (BNGO) Stock Price, News, Quote & History - Yahoo Finance
NasdaqCM - Delayed Quote USD

Bionano Genomics, Inc. (BNGO)

1.1400 +0.0300 (+2.70%)
At close: May 17 at 4:00 PM EDT
1.1300 -0.01 (-0.88%)
After hours: May 17 at 7:54 PM EDT
Loading Chart for BNGO
DELL
  • Previous Close 1.1100
  • Open 1.1200
  • Bid 1.1200 x 400
  • Ask 1.1500 x 200
  • Day's Range 1.0900 - 1.1450
  • 52 Week Range 0.7100 - 8.2000
  • Volume 865,051
  • Avg. Volume 1,421,228
  • Market Cap (intraday) 76.217M
  • Beta (5Y Monthly) 2.41
  • PE Ratio (TTM) --
  • EPS (TTM) -6.8100
  • Earnings Date Aug 7, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.33

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

www.bionano.com

344

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BNGO

Performance Overview: BNGO

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BNGO
39.68%
S&P 500
11.18%

1-Year Return

BNGO
82.73%
S&P 500
29.04%

3-Year Return

BNGO
97.89%
S&P 500
27.06%

5-Year Return

BNGO
96.38%
S&P 500
84.38%

Compare To: BNGO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BNGO

Valuation Measures

Annual
As of 5/16/2024
  • Market Cap

    74.21M

  • Enterprise Value

    59.31M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.18

  • Price/Book (mrq)

    0.90

  • Enterprise Value/Revenue

    1.58

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -33.39%

  • Return on Equity (ttm)

    -134.56%

  • Revenue (ttm)

    36.12M

  • Net Income Avi to Common (ttm)

    -232.49M

  • Diluted EPS (ttm)

    -6.8100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    66.77M

  • Total Debt/Equity (mrq)

    82.59%

  • Levered Free Cash Flow (ttm)

    -97.73M

Research Analysis: BNGO

Analyst Price Targets

2.00
6.33 Average
1.1400 Current
11.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: BNGO

People Also Watch